Economic Evaluation of Denosumab Compared With Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients With Bone Metastases

Journal of Managed Care Pharmacy
doi 10.18553/jmcp.2011.17.8.621
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Academy of Managed Care Pharmacy

Related search

Zoledronic Acid and Skeletal Complications in Patients With Solid Tumors and Bone Metastases

Cancer
Cancer ResearchOncology
2008English

CS4 Bone Lesions in Hormone Refractory Prostate Cancer (HRPC)

Japanese Journal of Urology
Urology
2006English

Hormone-Refractory Prostate Cancer

English

Efficacy of Combination Therapy With Zoledronic Acid and Cetuximab for Unresectable Rectal Cancer With Bone Metastases: A Case Report

Molecular and Clinical Oncology
Cancer ResearchOncology
2019English

PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Radium-223 for the Treatment of Patients With Castration-Resistant Prostate Cancer With Bone Metastases

Medical Council
2018English

PSA Levels and Prognosis in Patients With Hormone-Refractory Prostate Cancer Treated With Low-Dose Dexamethasone

Japanese Journal of Urology
Urology
2001English

Cost-Effectiveness of Regular Utilization of Zoledronic Acid for Developed Bone Metastases From Advanced Breast Cancer in Chinese Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Case of Breast Cancer Associated With Multiple Bone Metastases Successfully Treated With Denosumab and Capecitabine

Juntendo Medical Journal
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy